Comparative Pharmacology
Head-to-head clinical analysis: NEO POLYCIN versus PEDIAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO POLYCIN versus PEDIAZOLE.
NEO-POLYCIN vs PEDIAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis. Polymyxin B is a polypeptide antibiotic that disrupts bacterial cell membrane permeability by interacting with phospholipids. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
Pediazole is a combination of erythromycin (a macrolide antibiotic that binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis) and sulfisoxazole (a sulfonamide that inhibits dihydropteroate synthase, blocking folic acid synthesis).
Apply a thin layer to the affected area 3 to 4 times daily. Use a unit-dose ointment or eye drops: 1 to 2 drops in the affected eye(s) every 4 to 6 hours, or more frequently as needed.
Adults: 1 mg/kg intravenously every 6 hours.
None Documented
None Documented
Neomycin: 2-3 hours in patients with normal renal function; prolonged to 12-24 hours in renal impairment. Polymyxin B: 6-8 hours. Bacitracin: 1.5 hours (if absorbed); typically not systemically available.
Terminal half-life is approximately 6-8 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment.
Neomycin: ~30-50% of absorbed dose excreted renally as unchanged drug; unabsorbed drug eliminated fecally. Polymyxin B: minimal renal excretion (<1% of dose); primarily eliminated via non-renal routes, possibly biliary or metabolic. Bacitracin: negligible renal excretion after topical use; systemic absorption minimal.
Renal excretion of unchanged drug accounts for approximately 70-80% of the dose; biliary/fecal elimination is minor (<10%).
Category C
Category C
Antibiotic Combination
Antibiotic Combination